

MAY - 5 1998

ASSIST OF PAT Washing

UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

#24

Todd M. Crissey
Patent Department
WARNER-LAMBERT COMPANY
2800 Plymouth Road
Ann Arbor, MI 48105

In Re: Patent Term Extension
Application for
U.S. Patent No. 4,260,769

NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,260,769, which claims the human drug product CEREBYX® (fosphenytoin sodium), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be five years.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue a certificate of extension, under seal, for a period of five years.

The period of extension has been calculated using the Food and Drug Administration determination of the length of the regulatory review period published in the Federal Register of March 20, 1997 (62 Fed. Reg. 13387). Under 35 U.S.C. § 156(c):

Period of Extension = 1/2 (Testing Phase) + Approval Phase

= $\frac{1}{2}(3,218) + 530$

= 2,139 days (5.86 years)

Since the regulatory review period began May 4, 1986, after the patent issue date (April 7, 1981), the entire period has been considered in the above determination. No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

The five year limitation of 35 U.S.C. § 156(g)(6)(B) applies in the present situation because the patent was issued before the date of enactment (September 24, 1984) of 35 U.S.C. § 156, but no action described in 35 U.S.C. § 156(g)(6)(B) was taken before the date of enactment (the date that the request for exemption became effective was May 4, 1986). Since the period of extension calculated under 35 U.S.C. § 156(c) for the patent cannot exceed five years under 35 U.S.C. § 156(g)(6)(B), the period of extension will be for five years.

The 14 year limitation of 35 U.S.C. § 156(c)(3) does not operate to further reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.:

4,260,769

Granted:

April 7, 1981

Original Expiration Date:

April 7, 1998

Applicant:

Valenino J. Stella et al.

Owner of Record:

Merck & Co., Inc.

Title:

5,5-Diphenylhydantoins

Classification:

548/112

Product Trade Name:

CEREBYX® (fosphenytoin sodium)

Term Extended:

Five years

Any correspondence with respect to this matter should be addressed as follows:

By mail:

Assistant Commissioner for Patents

Box Patent Ext.

Washington, D.C. 20231

By FAX:

(703) 308-6916

Attn: Special Program Law Office

Telephone inquiries related to this determination should be directed to the undersigned at (703) 306-3159.

Karin L. Tyson

Senior Legal Advisor

Special Program Law Office

Office of the Deputy Assistant Commissioner

for Patent Policy and Projects

cc:

Ronald L. Wilson, Director

RE: CEREBYX®

Health Assessment Policy Staff

Office of Health Affairs (HFY-20) Food and Drug Administration

Food and Drug Administration 5600 Fishers Lane, Room 15-22

Rockville, MD 20857

FDA Docket No.: 96E-0442